In aggregate, our data suggests that catalytic mTOR inhibition should be investigated in RCC and that the compensatory upregulation of MEK/ERK signaling may actually be a potential synthetic vulnerability in RCC. The gene discussed is MAP2K7; the disease is renal cell carcinoma.